NEW YORK (GenomeWeb News) – OriGene Technologies today announced the completion of its $21.3 million Series C financing round.
Qiming Venture Partners and Kleiner Perkins Caufield Byers China led the round, while existing investor IDG-Accel also participated, OriGene said.
The company intends to use the financing to "advance our growth strategy and operations," Wei-Wu He, OriGene's chairman and CEO, said in a statement, without elaborating.
Based in Rockville, Md., the company develops genomic research and diagnostic products. Its flagship product is the cDNA clone collection, a searchable gene bank with more than 30,000 human full-length TrueClone cDNA collections and more than 25,000 TrueORF cDNA clones, it said on its website.
Additionally, the company has developed "ultra-sensitive" monoclonal antibodies called UltraMAB.